BCIS ACI 2023­ – Dr Angela Hoye (Hull & East Yorkshire Hospitals, UK), is joined by Dr Rod Stables (Liverpool Heart and Chest Hospital, UK), Dr Anthony Mathur (Barts Health NHS Trust, UK) and Dr Sen Devadathan (Royal Cornwall Hospitals NHS Trust, UK) to have a critical discussion on the BCIS-REVIVED trial and what it means for patients with ischemic left ventricular dysfunction in 2023.

Data from REVIVED-BCIS2 was announced at ESC 2022. The trial showed no benefit to revascularization by percutaneous coronary intervention (PCI) in patients with severe ischaemic left ventricular systolic dysfunction, as compared with optimal medical therapy. For a deep dive into the results watch this Late-breaker Discussion with Dr Harriette Van Spall and principal investigator, Dr Divaka Perera.

00:57: Strengths and Flows of the REVIVED-BCIS2 trial

3:19: Reception of REVIVED-BCIS2 trial: Recruitment & Power

5:42: Perspectives on patient selection by participating faculty, Dr Mathur & Dr Stables

7:07: REVIVED impact on practice

9:00: Mortality rate of patients with ischaemic cardiomyopathy in the REVIVED trial

11:13: REVIVED sub-studies: What data should we expect?

12:05: Assessing patients for viability for PCI

16:00: Gender representation in REVIVED

16:38: Considerations for practice in light of the REVIVED data

Recorded on-site at BCIS ACI 2023, London.

Editor: Mirjam Boros

Videographer: Tom Green